Background-Massively parallel sequencing to identify rare variants is widely practiced in medical research and in the clinic. Genome and exome sequencing can identify the genetic cause of a disease (primary results), but it can also identify pathogenic variants underlying diseases that are not being sought (secondary or incidental results). A major controversy has developed surrounding the return of secondary results to research participants. We have piloted a method to analyze exomes to identify participants at risk for cardiac arrhythmias, cardiomyopathies, or sudden death. Methods and Results-Exome sequencing was performed on 870 participants not selected for arrhythmia, cardiomyopathy, or a family history of sudden death. Exome data from 22 cardiac arrhythmia-and 41 cardiomyopathy-associated genes were analyzed using an algorithm that filtered results on genotype quality, frequency, and database information. We identified 1367 variants in the cardiomyopathy genes and 360 variants in the arrhythmia genes. Six participants had pathogenic variants associated with dilated cardiomyopathy (n=1), hypertrophic cardiomyopathy (n=2), left ventricular noncompaction (n=1), or long-QT syndrome (n=2). Two of these participants had evidence of cardiomyopathy and 1 had left ventricular noncompaction on echocardiogram. Three participants with likely pathogenic variants had prolonged QTc. Family history included unexplained sudden death among relatives. Conclusions-Approximately 0.5% of participants in this study had pathogenic variants in known cardiomyopathy or arrhythmia genes. This high frequency may be due to self-selection, false positives, or underestimation of the prevalence of these conditions. We conclude that clinically important cardiomyopathy and dysrhythmia secondary variants can be identified in unselected exomes. (Circ Cardiovasc Genet. 2013;6:337-346.) The online-only Data Supplement is available at http://circgenetics.ahajournals.org/lookup/suppl/
M assively parallel sequencing (MPS), either whole genome sequencing or whole exome sequencing (WES), has been successful in facilitating the discovery of mutations for Mendelian disorders and more common conditions such as diabetes mellitus. Clinical MPS is also available, allowing thousands of research subjects and increasing numbers of patients to undergo this test. The highly parallel nature of MPS ensures that many genes other than those being targeted are evaluated. As a result, secondary (or incidental) genetic data on patients are rapidly accumulating. The majority of these secondary variants are benign or variants of uncertain significance. However, a few are expected to be clinically relevant. 1 There is considerable debate regarding the responsibilities of researchers and clinicians in returning secondary genetic variants. [2] [3] [4] The challenges are formidable-while recognizing that clinically important genetic results may be present in MPS datasets, researchers and clinicians must develop approaches to dealing with secondary variants that appropriately balance the sensitivity and falsepositive rates of this testing.
Clinical Perspective on p 346
We previously evaluated secondary variants in cancer susceptibility genes, showing that the detection of these mutations is practicable albeit challenging. 1 As part of our continuing efforts to address the issue of secondary variants, we selected 22 arrhythmia-and 41 cardiomyopathy-associated genes for study. We selected these phenotypes because they have welldelineated diagnostic criteria, effective treatments are available, and causative mutations have been identified.
To study the feasibility and use of identifying highly penetrant secondary arrhythmia-and cardiomyopathy-associated gene variants from WES data, we analyzed 870 participants who were not preselected for a personal or family history of arrhythmia, cardiomyopathy, or sudden cardiac death. We analyzed the WES data for variants in these genes, filtered them, and evaluated the phenotypes and family histories of those participants with predicted pathogenic variants. We present our approach, findings, and challenges in interpretation using available genetic and phenotypic data coupled with information from databases and literature for the identification of highly penetrant arrhythmia-and cardiomyopathy-associated gene variants in an unselected cohort.
Patients and Methods

Study Participants
Selection criteria for ClinSeq participants have been described. 5 Participants between 45 and 65 years of age were consented for initial phenotyping, which included clinical laboratory tests, 5 ECG, echocardiogram (ECHO), multidetector computed tomography coronary calcium, WES or whole genome sequencing, and return of results. Participants were selected with a spectrum of coronary artery disease risk (10- year Framingham risk <5%, 5%-10%, >10%, and a group with known coronary artery disease). These participants were not selected for a history of arrhythmia, cardiomyopathy, or family history of sudden cardiac death. The National Human Genome Research Institute's Institution Review Board reviewed and approved this study.
Gene List
We developed a list of 41 cardiomyopathy-associated genes ( Table I  in , short-QT syndrome). This list comprises conditions inherited in an autosomal dominant pattern with the exception of CASQ2-associated catecholaminergic polymorphic ventricular tachycardia, which is inherited in an autosomal recessive pattern. Cardiomyopathy-associated genes attributed to metabolic or developmental syndromes were excluded.
Next-Generation Sequencing and Variant Analysis
DNA isolation, library preparation, sequencing, alignment, base calling, and filtering for sequence and base-calling metrics were performed as described. 1 Reads were aligned to hg18 (NCBI build 36) with Casava 1.8 ELAND (Illumina) and cross_match (http://www.phrap.org/phredphrapconsed.html). Genotypes were determined with most probable genotype score. 6 Our goal was to identify variations highly likely to be pathogenic while minimizing false positives; therefore, sensitivity was sacrificed. We analyzed nonsense, frameshift, splice-site, and nonsynonymous variants in the above-listed genes in 870 participants. Variants were graded using a modified version of an established scale 1 from class 0 (poor quality) to class 5 (pathogenic). Variants that failed quality filters were designated class 0. Our goal was to identify rare, highly penetrant disease susceptibility alleles rather than common alleles with modest disease liability. We did not look for gene-gene interactions from more common alleles (minor allele frequency≥0.015) as the size of our cohort (n=870) limited the power to detect additive effects. We reasoned that no single allele with a frequency of >0.01 in ClinSeq or Single Nucleotide Polymorphism Database minor allele frequency of >0.015 (Single Nucleotide Polymorphism Database 7 build 132, minimum 120 chromosomes) could cause a disorder with a prevalence of 1/500 and designated these class 1.
The most common of the conditions analyzed here were DCM and HCM with a frequency of ≈1/500. 8, 9 We used the allele frequency from ClinSeq and the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP; allele frequencies downloaded November 24, 2012) to set a threshold such that any single variant that occurred at a frequency greater than the published estimates for the disease prevalence (>1/2000 Brugada syndrome, 10 >1/10 000 catecholaminergic polymorphic ventricular tachycardia, 11 >1/2500 LQTS, 12 >1/1000 arrhythmogenic right ventricular cardiomyopathy, 13 >1/500 HCM, 12 and >1/500 DCM) 8, 14, 15 was likely not pathogenic (class 2) irrespective of any prior pathogenic classification ( Figure 1 ). For all other variants, the Human Gene Mutation Database (HGMD 16 ) and locus-specific databases 17, 18 were consulted, relevant publications were reviewed, and variants were assigned to pathogenicity classes according to the criteria in Table 1 . Variants were designated class 2 (likely benign) if they had been reported multiple times as benign or multiple lines of evidence argued against pathogenicity. Evidence against pathogenicity included comparable frequency in cases and controls, co-occurrence with a known pathogenic mutation, and/or normal functional data. Novel missense or in-frame insertion/deletion variants were assigned to class 3 (variant of uncertain significance). Missense and in-frame insertion/deletion variants reported a single time as pathogenic without supporting evidence or multiple times with evidence against pathogenicity and loss of function (ie, nonsense, frameshift, or splice-site) variants reported once with single evidence against pathogenicity or multiple times with multiple evidence against pathogenicity were also assigned to class 3. For novel nonsense, frameshift, and splice-site variants, the Variants were filtered on genotype quality, coverage, and allele frequency. Variants occurring at a frequency greater than the disease prevalence were designated class 2. Remaining variants were assigned pathogenicity scores based on data in the Human Gene Mutation Database (HGMD) and locus-specific databases (LSDBs; characteristics of the gene and the variant, and the participant's family history, were considered. Variants were designated class 4 (likely pathogenic) if there was a single case reported as pathogenic with supporting evidence (ie, segregation, absent in controls, functional studies), 2 cases reported as pathogenic without additional evidence for or against pathogenicity, or ≥3 cases without sufficient racematched control data to exclude a high population frequency. Class 5 was assigned when 2 cases with additional supporting evidence were presented or ≥3 cases were reported as pathogenic without evidence against pathogenicity and with sufficient race-matched control data to exclude a high population frequency. Two investigators analyzed variants and assigned a consensus pathogenicity score. Variants are described by their predicted protein changes in the text, but both the cDNA and predicted protein changes are described in the tables.
Statistical Analyses
Participants with arrhythmia-or cardiomyopathy-associated rare variants (classes 4-5) were grouped, respectively, and compared with participants without identifiable class 3 to 5 arrhythmia-or cardiomyopathy-associated variants. Due to the high number of variants in the cardiomyopathy dataset, there were no controls with homozygous wildtype genotype across all class 3 to 5 variant positions. Because the majority of TTN variants are unclassified, class 3 TTN variants (n=366) were not considered in selecting cardiomyopathy controls (cardiomyopathy control group I, n=67). Cardiomyopathy-associated rare variants were also compared against all individuals with class 1 to 3 variants (cardiomyopathy control group II, n=838). Fisher's exact test was used to compare categorical variables, and Mann-Whitney U test was used for group comparisons of continuous clinical variables. Variants that passed quality and frequency filters were assigned to pathogenicity classes based on data available in HGMD, locus-specific databases, and family history ( Figure 1 ). dbSNP indicates Single Nucleotide Polymorphism Database; ESP, Exome Sequencing Project; FHx, family history; LOF, loss of function; MAF, minor allele frequency; and VUS, variants of unknown significance.
Calculations were performed on GraphPad Instat v.3.1.a and presented as mean±SD. Multiple linear regression was used to compute effect estimates of independent variables (age, body mass index, history of hypertension, race, sex, use of antihypertensive medications) on ECG and ECHO parameters, identify confounding covariates, and calculate adjusted means. The leaps and effects packages (R software v.2.15.2) were used for linear model analyses and selection. Results are shown as mean±SEM. A 2-tailed P value of <0.05 was considered significant. A Benjamini-Hochberg correction was applied to decrease false positives due to multiple testing. Multi-dimensional scaling in PLINK was used to assess population structure.
Results
Demographics
There were 870 individuals analyzed in this study. Most were white (89%) and non-Hispanic (96.3%). The median age at consent was 57 years (range 45-65). There was a slight preponderance of men (50.3%).
Sequence Data
For the 870 exomes, 68.2 billion reads were generated resulting in 6.13 trillion bp of sequence and 2 452 318 unique variants. Copy number variants and indels >10 bp were not assessed. A total of 244 541 variants were nonsynonymous, frameshift, nonsense, or splicing. The 41 cardiomyopathy-associated genes comprised 185 997 bp of targeted coding sequence. Average gene coverage ranged from 51.8% (MYBPC3) to 100% (PLN) with a median of 97.6%. The 22 arrhythmia-associated genes comprised 72 984 bp of targeted coding sequence. Average gene coverage ranged from 60.3% (HCN4) to 99.9% (CACNB2, KCNE2, and KCNE3) with a median of 97.4% ( Figure 2 ).
Variant Classification
There were 1367 variants identified in the 41 cardiomyopathyassociated genes (no variants were identified for ACTC1 or MYL3; Table I in the online-only Data Supplement) and 360 variants in the 22 arrhythmia-associated genes ( Table II in the online-only Data Supplement). Fifteen variants (cardiomyopathy, n=9; arrhythmia, n=6) did not meet the quality metrics and were designated score 0 ( Figure 3 ). There were 440 variants designated class 1 (cardiomyopathy, n=363; arrhythmia, n=77) due to frequency (>0.01 ClinSeq or NHLBI ESP and >0.015 Single Nucleotide Polymorphism Database; Figure 1 ). There were 380 variants designated class 2 (cardiomyopathy, n=282; arrhythmia, n=98) because of allele frequency in ClinSeq or NHLBI ESP exceeding the disease prevalence. The remainder of the variants (cardiomyopathy, n=713; arrhythmia, n=179) were scored based on information in HGMD and/or locus-specific databases. Variants listed as a polymorphism in HGMD or benign polymorphism in locus-specific databases were scored class 2 after literature review (cardiomyopathy, n=4; arrhythmia, n=5). Of the remaining variants, 832 were scored class 3 (uncertain; cardiomyopathy, n=677; arrhythmia, n=155; Figure 3 ) because of no publications, or no HGMD/locusspecific databases entry, or the predicted protein change was in a transcript other than the HGMD reference or single case reports without supporting evidence or with conflicting evidence. Forty-five variants were scored class 4 (likely pathogenic; cardiomyopathy, n=28; arrhythmia, n=17) based on a single reported case with supporting evidence or 2 reported cases with no evidence against or have a predicted loss of function variant when loss of function mutations have been reported as causative, but the proband's family history was equivocal, or if there were insufficient race-matched control data. Six variants were designated class 5 (pathogenic; cardiomyopathy, n=4; arrhythmia, n=2; Figure 3 ) based on ≥3 reported cases of pathogenicity and no evidence against or 2 reported cases with additional supporting evidence, and sufficient race-matched control data are available. Details of the scoring are available (Tables I-IV in the online-only Data Supplement). All reported class 4 to 5 variants were confirmed by Sanger sequencing.
Individuals With Class 5 Cardiomyopathy-Associated Variants
Four cardiomyopathy-associated variants identified in 1 participant each (MYBPC3 p.Gly490Arg, MYBPC3 p.Arg495Gln, MYH7 IVS8+1G>A, and PLN p.Leu39X) were scored class 5 ( Table 2 ). Participant 182 262 had MYBPC3 p.Gly490Arg, a missense mutation reported in 3 individuals with 3 different phenotypes (DCM, 19 HCM, 20 and LVNC 21 ). He was a 56-year-old white male with a normal ECG and mild asymmetrical basal septal hypertrophy and normal left ventricular ejection fraction (LVEF 65%) on ECHO. He had a history of elevated cholesterol, hyperuricemia, and renal cancer diagnosed at age 55, but no hypertension. His family history was significant for maternal grandparents dying from congestive heart failure, a sister diagnosed with cardiomyopathy in her 60s, a paternal cousin who died of congestive heart failure at age 68, and a paternal uncle who died at age 2. MYBPC3 p.Gly490Arg was reported in NHLBI ESP with a minor allele frequency of 3/8476. Participant 135 629 had MYBPC3 p.Arg495Gln, a missense mutation cosegregating with HCM in 1 family, 22 reported in 1 sporadic HCM 20 and associated with left ventricular hypertrophy in asymptomatic relatives. 23 He was a 62-year-old white male who had sinus bradycardia and left anterior fascicular block on ECG and a mildly dilated right atrium and ventricle with normal LVEF (57%) on baseline ECHO. He was subsequently diagnosed with asymptomatic atrial fibrillation on preop ECG and mild concentric left ventricular hypertrophy in 2012. His sister developed intermittent atrial fibrillation in her 60s, and his mother had severe atrial fibrillation. MYBPC3 p.Arg495Gln was not identified in NHLBI ESP.
Participant 120 682 has MYH7 IVS8+1G>A, a splice variant that has been reported to cosegregate with LVNC in 2 families. 24 She was a 62-year-old white female with first-degree atrioventricular block on ECG and prominent trabeculations at the LV apex, with normal LVEF (60%) on ECHO. Follow-up cardiac MRI (2008, 2012; Figure 4 ) confirmed LVNC changes with normal LVEF (60%). Her family history was negative for cardiomyopathy or congestive heart failure; 1 daughter was noted to have a persistent high resting pulse (90s). MYH7 IVS8+1G>A was not identified in NHLBI ESP.
Participant 114 451 had PLN p.Leu39X, a loss of function mutation identified in 3 unrelated families with DCM. 25 She was a 57-year-old white female with a normal ECG, thickened aortic valves, moderate aortic regurgitation, and normal LVEF (60%) on ECHO. She had a brother with coronary artery disease and stent placement at age 61 and a father with a myocardial infarction and placement of a cardiac defibrillator and dual chamber pacemaker at age 61. PLN p.Leu39X was not identified in the NHLBI ESP.
See Table V in the online-only Data Supplement for phenotypic summary of class 4 cardiomyopathy variants.
Class 5 Arrhythmia-Associated Variants
Two variants were scored class 5 in the 22 arrhythmia-associated genes ( Table 3) .
Participant 155 279 had KCNE1 p.Arg98Trp. She was a 62-year-old white female with a normal ECG and ECHO. Her family history included a father who died of a myocardial infarction at age 45, a sister who had 2 myocardial infarctions and valve surgery before age 70, and another sister with stress-associated palpitations. KCNE1 p.Arg98Trp was identified in 2 individuals diagnosed with LQTS 26, 27 and not identified in the NHLBI ESP. Functional studies of this variant showed a positive shift in voltage-dependent activation of the slow potassium channel (I Ks ) and defects in trafficking KCNQ1. 28 Participant 173 996 had KCNH2 p.Arg312Cys. He was a 55-year-old white male with sinus bradycardia (not on β-blockers), first-degree atrioventricular block, moderate mitral regurgitation, and impaired left ventricular relaxation on ECHO. He had a history of an episode of palpitations without syncope and a family history of 2 paternal aunts and 1 uncle who died suddenly in their 70s from unknown causes. KCNH2 p.Arg312Cys was identified in 3 unrelated individuals, 2 with LQTS, 26,29 1 referred for LQTS genetic testing, 30 and was not identified in the NHLBI ESP.
See Table VI in the online-only Data Supplement for phenotypic summary of class 4 arrhythmia variants.
Comparison of Baseline Phenotypic Data
Individuals with class 4 to 5 arrhythmia-associated variants were assessed as a group (n=19) for comparison of age, sex, race, history of hypertension, baseline ECG, and ECHO measurements to participants who did not have identifiable class 3 to 5 variants in the respective arrhythmia-associated genes (n=42). Individuals with class 4 to 5 cardiomyopathy-associated variants (n=32) were compared with 2 control groups as described. The groups were similar in regard to age, sex, and race. There was a lower percentage of individuals with a history of hypertension in the arrhythmia cases and a higher percentage in the cardiomyopathy cases compared with controls, but the difference was not significant. There were no significant differences in QTc interval, septal thickness, left ventricular mass, or ejection fraction in the respective cases and controls both before and after adjustment for covariates (data not shown).
Discussion
We piloted a method to identify rare, high-penetrant cardiomyopathy-and arrhythmia-associated alleles. Analysis of WES from 870 participants not selected for a clinical phenotype or family history of arrhythmia or cardiomyopathy identified 6 individuals with class 5 (pathogenic) variants. Three of these individuals had subclinical evidence of cardiomyopathy at enrollment in ClinSeq and would not otherwise have sought medical evaluation. Consensus recommendations for asymptomatic, mutation-positive individuals are available, 9 but there are still many areas where more research is needed to formulate recommendations.
Individual 182 262 (MYBPC3 p.Gly490Arg) had asymptomatic asymmetrical basal septal hypertrophy when he enrolled in ClinSeq at age 56. On follow-up, he related intermittent caffeine-associated palpitations (×2 years) but no dyspnea on exertion, chest pain, or syncope. His family history is significant for a sister developing HCM in her late 60s. Individuals with MYBPC3 mutations have been reported to display age-dependent penetrance for HCM. 22 There are no specific recommendations for individuals with incidental HCM susceptibility variants. We applied American Heart Association recommendations for genotype-positive/asymptomatic individuals with HCM mutations identified through family studies to our participants. Recommendations for participant 182 262 include (1) periodic assessment with ECG and transthoracic ECHO to screen for dysrhythmia and LV dysfunction; (2) his palpitations should be evaluated with a 24-h Holter to screen for ventricular tachycardia; (3) optimal management of his hyperlipidemia and maintenance of normal blood pressure and weight; and (4) cascade genetic testing for his first-degree relatives. 9 We are applying those recommendations to this participant, although we recognize those recommendations did not consider individuals identified by WES.
Participant 135 629 (MYBPC3 p.Arg495Gln) had an asymptomatic dilated right atrium and ventricle at age 62. At follow-up, he reported dyspnea on exertion at age 66. Preoperative ECG showed new onset atrial fibrillation, and ECHO showed mild concentric left ventricular hypertrophy and decreased LVEF (50%). American Heart Association recommendations for him include (1) anticoagulation with warfarin for stroke prevention, (2) annual ECG to monitor for asymptomatic progressive conduction block or rhythm changes, (3) transthoracic ECHO every 1 to 2 years to reassess the degree of HCM and monitor for left ventricular outflow tract obstruction, and (4) initiation of cascade genetic testing for his first-degree relatives. 9 Participant 120 682 (MYH7 IVS8+1G>A) was asymptomatic when she enrolled in ClinSeq at 62 years of age. She has no complaints of dyspnea on exertion, palpitations, or fainting on follow-up at 66 years of age. There are no set recommendations for asymptomatic individuals with LVNC. Monitoring is tailored to individual symptoms. 31 The consulting cardiologist recommended repeat cardiac MRI or ECHO every 2 years to reassess the severity of the aortic regurgitation and left ventricular function. We recommended genetic testing of her firstdegree relatives.
These data show that a focused analysis of MPS data can successfully identify incidental, medically relevant genetic variants that may benefit research participants. This genomicsfirst approach is a major paradigm shift for medical practice as it changes the focus from diagnosis and treatment of manifest disease to identification, monitoring, and early treatment aimed at disease modification for asymptomatic individuals with genetic susceptibility. The potential benefit of early detection will require clinical studies and long-term follow-up to establish evidence-based effective monitoring and prophylaxis.
The 3 remaining individuals (PLN p.Leu39X, KCNE1p. Arg98Trp, and KCNH2 p.Arg312Cys) were nonpenetrant. Long-term follow-up of these individuals and family studies may help to elucidate genetic and environmental factors that influence incomplete penetrance and variable expressivity.
The ClinSeq frequency of 2/870 for LQTS-associated class 5 variants is above the reported prevalence of 1/2500 for LQTS. 12 We suggest 4 possible explanations for the high observed frequency of LQTS variants: first, participants may have selfselected when enrolling in ClinSeq. Among the 19 participants with class 4 or 5 arrhythmia-associated variants, 8 had mild bradycardia and 1 developed left bundle-branch block without evidence of coronary artery disease in middle age, whereas several of the participants had family histories of sudden death that might have led them to enroll in the study. Second, it is possible that the true prevalence of LQTS is underestimated.
Third, it is possible that the penetrance of these disorders is lower than hitherto appreciated, and these individuals are (to date) nonpenetrant. Finally, it is possible that some of these variants are actually benign and that the literature supporting their pathogenicity is incorrect. There are no formal standards for classifying a variant as causative, and the genetics literature and mutation databases contain substantial numbers of incorrect assignments of pathogenicity. 32, 33 Data from cardiomyopathy and dysrhythmia disease registries are starting to fill in this void by providing estimates of the frequency of rare variants in healthy controls, 31 but additional criteria are needed to support or refute pathogenicity, such as in vitro functional studies or long-term follow-up of healthy controls.
Deciding which secondary variants to return remains a challenge. We suggest following NHLBI working group guidelines 34 to determine which variants to return. NHLBI criteria for return of genetic results include (1) variant has established, important health implications; (2) the genetic finding is actionable; (3) testing is analytically valid; and (4) the participant has consented to receive his/her genetic results. Additionally, the American College of Medical Genetics and Genomics has released recommendations for the reporting of incidental findings from clinically indicated (ie, not research) sequencing (www.acmg.net). Their recommended minimum gene list to be considered for return of incidental findings includes a number of disorders studied here. Even in asymptomatic individuals, we suggest that there are potential clinical benefits for returning class 5 variants that can be derived from the individual's increased awareness of changes in symptomatology and enhanced medical surveillance. Our approach is similar to proposals for using genetic data to identify asymptomatic family members with LQTS mutations who should be followed and medically managed if indicated 35 and American College of Cardiology Foundation/American Heart Association guidelines recommending periodic clinical assessment for genotypepositive/asymptomatic individuals with pathogenic mutations who do not express the HCM phenotype. 9 These variants can be considered secondary (or incidental) findings because neither we nor the patients were seeking genetic test results for these traits at the time the patients were consented. The secondary variants issue is being debated in both the research and clinical testing realms and has spawned efforts to develop policies to handle such results. 4, 34 These policies support the notion that secondary findings of high medical importance should be sought and returned to research participants by a team of experts supported by a genetic counselor. Others, however, disagree and suggest that individual clinical results should not be returned to research participants, even when medically compelling, to prevent therapeutic misconception and avoid stressing research resources. Because we are studying the impact of returning results in ClinSeq, we have opted to returned class 5 and some class 4 (ie, those with abnormal findings or suspicious family history) variants to our participants. We recognize that other clinical researchers may reach different conclusions based on their study designs and institution review board protocols. In the clinical realm, the American College of Medical Genetics and Genomics recommendations are controversial and will undoubtedly evolve, but they are a starting point for developing an approach to incidental variants. Among the 6 class 5 variants we detected, 4 met the current American College of Medical Genetics and Genomics incidental findings reporting recommendations (MYBPC3 p.Gly490Arg, MYBPC3 p.Arg495Gln, MYH7 IVS8+1G>A, and KCNH2 p.Arg312Cys), but 2 of our class 5 variants are in genes not on the American College of Medical Genetics and Genomics list (PLN p.Leu39X and KCNE1 p.Arg98Trp). As in all areas of medicine, clinicians must use their judgment in interpreting and returning incidental findings. The data presented here do not lead to specific conclusions supporting the return of results in the research or clinical setting, but they do provide data on the feasibility and yield of such an analysis.
In the clinical setting, identifying apparently pathogenic gene variants in an asymptomatic individual will require a multi-step process to determine clinical significance and appropriate medical management. Research on the clinical use and implementation of individual genomic information must be supplemented by additional clinical evaluation focused on the disease in question. This iterative evaluation of asymptomatic individuals with potentially pathogenic variants will be important as studies have shown that family members with normal QTc and pathogenic arrhythmia variants have a 4% risk of developing an aborted cardiac arrest or sudden cardiac death 35 and that individuals with MYBPC3 mutations and no HCM have evidence of impaired myocardial energetics, 36 illustrating that an asymptomatic individual does not necessarily have a benign clinical outcome.
Estimating disease risk from an individual's genetic profile for disease prevention and treatment is the objective of individualized medicine. Although genomic medicine may appear within reach, the development and finetuning of the analyses and clinical interpretation of sequencing data remains a major hurdle. One challenge in the interpretation of WES is to minimize false positives. This problem is not trivial as the probability of false-positive findings increases substantially in an asymptomatic cohort. Single-gene mutation screening for cardiomyopathy or dysrhythmia is not indicated in the general population due to the large number of people identified with variants of uncertain significance. 31 Although we support recommendations that proscribe gene screening for LQTS or DCM variants in the general population, this must be considered as distinct from the secondary variant issue. An appropriate analogy is the chest radiograph-although it is inappropriate to screen the general population for lung cancer, 37 all radiologists report lung lesions noted incidentally when a chest radiograph is performed, irrespective of the indication, while recognizing that most such masses are not cancerous. 38 Our challenge is to improve the positive predictive value and sensitivity of genomic screening so that useful medical predictions can be generated.
Limitations of this study include decreased sequence coverage of MYBPC3 because of the capture kit used on the initial 391 DNA samples not targeting this gene. Hence, there may be additional MYBPC3 disease-associated variants present in our cohort of 870 that were not picked up by WES. ClinSeq participants are not representative of the general population; as a group, they have above-average income, have a high level of education, and are highly motivated to participate in research. 39 Another source of potential bias is that some of our participants may have self-selected for enrollment based on their personal or family histories; hence, the frequency of pathogenic variants may not be representative of the general population.
In summary, we analyzed 870 WES to identify pathogenic arrhythmia-and cardiomyopathy-associated gene variants using an algorithm that filtered results based on genotype quality, frequencies, and published data from databases, and we identified 6 participants possessing pathogenic variants for DCM, HCM, LVNC, and LQTS. As with other Mendelian disorders, familial arrhythmias and cardiomyopathies exhibit variable expressivity, 40 reduced penetrance, 41 and environmental 42 and genetic modifiers 43 that pose challenges to the interpretation of gene variants. As such, these disease models serve as a paradigm to highlight the challenges in translating genomic sequence data into evidence-based medicine. Yet these data suggest that significant numbers of patients, in this case ≈0.5% of the participants, have a putative pathogenic secondary variant in a gene for these disorders.
Web Resources
Human Genome Variation Society Locus Specific Mutation Databases: http://www.hgvs.org/dblist/glsdb.html; Human Gene Mutation Database: http://www.hgmd.org/; Leiden Open Variation Database: http://www.lovd.nl/2.0/; NHLBI Exome Sequencing Project (ESP) Exome Variant Server: http://evs.gs.washington.edu/EVS/.
